Allergan gets NICE thumbs up for eye drug; Novartis wins new use for Lucentis;

@FiercePharma: Cephalon CEO up for $14M severance in Teva deal. Report | Follow @FiercePharma

> Allergan's Ozurdex drug has been recommended for reimbursement under Britain's state health system to treat an eyesight-endangering condition in which fluid builds up in the retina because of a clogged vein. Report

> Novartis has won final European clearance for broader use of its eye drug Lucentis, the Swiss drugmaker said, underscoring its effectiveness in treating eye diseases. News

> The FDA has issued a warning letter to Impax Laboratories over deficient sampling and testing of drugs at its plant in Hayward, CA.  Item

> Endo Pharmaceuticals sold $900 million of senior notes in two parts in the 144a private placement market, said a market source. Article

> Forest Laboratories agreed to repurchase another $500 million of common stock from Morgan Stanley, further accelerating its buyback plans. Story

> Dutch cancer test firm Agendia aims to raise up to 90 million euros ($132 million) in an initial public offering, testing the market with the first IPO in Amsterdam of a healthcare firm since the 2008 financial crisis. Report

Biotech News

@FierceBiotech: Ex-CRO workers alleged to have falsified data in Schering study. Report | Follow @FierceBiotech

@JohnCFierce: I wrote up Constellation back in 2008 as one of our Fierce 15s. Report | Follow @JohnCFierce  

> Stars align for Constellation as it adds $15M in venture funds. Report

> Roche's vemurafenib plays a starring role at ASCO. News

> With promising Ph3 data in hand, Incyte files for myelofibrosis drug OK. News

> Experimental oral contraceptive looks promising for men. Report

> Algeta shares spike on promising prostate cancer drug data. Article

> ASCO roundup: Fresh progress of Merck, Pfizer cancer drugs. Item

Biotech IT News

> DNA computer tackles problems with code of life. Story

> Exclusive CEO Q&A: BioClinica chief Mark Weinstein on firm's eClinical makeover. Interview

> OpenClinica rides open source model to gain paying EDC users. Piece

> Medidata adds Allscripts vet Shapiro to board. Report

> Nations advance systems to flag bad drug reactions. Item

> Aptiv Solutions advances with CRO-software combo. Report

Medical Device News

> Regenesis gets $5.3M in Series C. Report

> FDA urges industry to check Japanese parts for damage. Story

> J&J's Animas unit get CE mark for Animas Vibe. Item

> Straumann, Nobel Biocare drop bids for AstraTech. Report

> Medco, MolecularMD team on CML test. Article

And Finally... Prescribing a drug off-label when a licenced alternative exists increases patient safety risks and threatens the development of new medicines, according to the ABPI. Piece